23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Arrowhead Pharmaceuticals, Inc. › 2025-2026

Arrowhead Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Arrowhead Pharmaceuticals, Inc.’s Form 8-K, filed March 20, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 10Reported items
  • 377Asset managers, any item
  • 3,827Fund votes
  • March 19, 2026Meeting date

Results at a glance

Meeting of March 19, 2026: 7 items on Arrowhead Pharmaceuticals, Inc.’s Form 8-K, filed March 20, 2026: 7 passed (calculated).

Dissent

Significant dissent: 1 director (30.8% against).

  • Elect Director: Michael Perr 69% of votes cast Passed (calculated) Significant · 30.8% against

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Arrowhead Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Arrowhead Pharmaceuticals, Inc.

These tallies are Arrowhead Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed March 20, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arrowhead Pharmaceuticals, Inc. — official shareholder meeting results, meeting held March 19, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Christopher Anzalon 100,146,3661,622,01177,607 --17,955,558 98%Passed (calculated)—
Elect Director: Mauro Ferrar 99,784,8481,986,67874,458 --17,955,558 98%Passed (calculated)—
Elect Director: Hongbo L 92,692,4288,971,012182,544 --17,955,558 91%Passed (calculated)—
Elect Director: Adeoye Olukoto 100,808,855852,631184,498 --17,955,558 99.2%Passed (calculated)—
Elect Director: Michael Perr 70,427,87931,342,81475,291 --17,955,558 69%Passed (calculated)—
Elect Director: Victoria Vakiene 99,264,1912,506,05175,742 --17,955,558 98%Passed (calculated)—
Elect Director: William Waddill 91,907,4669,861,644256,341 --17,955,558 90%Passed (calculated)—

Source: Arrowhead Pharmaceuticals, Inc., Form 8-K, filed with the SEC on March 20, 2026 — read the filing on EDGAR.

How asset managers voted at the Arrowhead Pharmaceuticals, Inc. 2025-2026 meeting

377 asset managers disclosed a vote on at least one Arrowhead Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Arrowhead Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Election of Directors: Adeoye Olukotun

No official matchDIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR
Details: votes by 107 asset managers

The 107 asset managers below reported 50,336,475 for, 10,960 against, 25,221 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 50,336,475AGAINST: 10,960ABSTAIN: 25,221
Largest asset managers voting on “Election of Directors: Adeoye Olukotun” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6103 10For
Fidelity6,850,7530 00For
State Street3,210,7980 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan172,3680 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).

Elect Director: Christopher Anzalon

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 100,146,366AGAINST: 1,622,011
Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: Christopher Anzalone

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Christopher Anzalon”): 100,146,366 for, 1,622,011 against, per its Form 8-K filed March 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 50,336,391 for, 11,043 against, 25,220 abstained.

FOR
FOR: 50,336,391AGAINST: 11,043ABSTAIN: 25,220
Largest asset managers voting on “Election of Directors: Christopher Anzalone” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6085 00For
Fidelity6,850,7530 00For
State Street3,210,71781 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan172,3680 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).

Elect Director: Mauro Ferrar

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 99,784,848AGAINST: 1,986,678
Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: Mauro Ferrari

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mauro Ferrar”): 99,784,848 for, 1,986,678 against, per its Form 8-K filed March 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 50,298,877 for, 48,558 against, 25,220 abstained.

FOR
FOR: 50,298,877AGAINST: 48,558ABSTAIN: 25,220
Largest asset managers voting on “Election of Directors: Mauro Ferrari” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6076 00For
Fidelity6,850,7530 00For
State Street3,210,622176 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan172,3680 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).

Election of Directors: Michael S. Perry

No official matchDIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

59% of fund votes cast · no official result

FORAGAINST
Details: votes by 107 asset managers

The 107 asset managers below reported 29,457,122 for, 20,890,313 against, 25,220 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 29,457,122AGAINST: 20,890,313ABSTAIN: 25,220
Largest asset managers voting on “Election of Directors: Michael S. Perry” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock263,85314,510,585 00Against
Vanguard14,302,57538 00For
Fidelity2,843,9194,006,834 00Mixed
State Street3,210,622176 00For
Charles Schwab01,191,957 00Against
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust438,13825,480 00Mixed
Jackson National118,615280,477 00Mixed
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable114,090195,680 00Mixed
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC0218,394 00Against
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan0172,368 00Against
Lincoln Financial161,29810,350 00Mixed
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).

Elect Director: Victoria Vakiene

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 99,264,191AGAINST: 2,506,051
Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: Victoria Vakiener

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Victoria Vakiene”): 99,264,191 for, 2,506,051 against, per its Form 8-K filed March 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 50,336,470 for, 10,965 against, 25,220 abstained.

FOR
FOR: 50,336,470AGAINST: 10,965ABSTAIN: 25,220
Largest asset managers voting on “Election of Directors: Victoria Vakiener” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6058 00For
Fidelity6,850,7530 00For
State Street3,210,7980 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan172,3680 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).

Elect Director: William Waddill

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 91,907,466AGAINST: 9,861,644

Prior year: 90.6% for (March 12, 2025 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: Election of Directors: William Waddill

Arrowhead Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: William Waddill”): 91,907,466 for, 9,861,644 against, per its Form 8-K filed March 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 45,773,446 for, 4,573,989 against, 25,220 abstained.

FOR
FOR: 45,773,446AGAINST: 4,573,989ABSTAIN: 25,220
Largest asset managers voting on “Election of Directors: William Waddill” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,290,44112,172 00For
Fidelity2,897,4103,953,343 00Mixed
State Street3,210,7980 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National118,615280,477 00Mixed
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
JPMorgan0172,368 00Against
Lincoln Financial161,29810,350 00Mixed
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For

Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).

Election of Directors: Hongbo Lu

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

91% of fund votes cast · no official result

FOR
Details: votes by 103 asset managers

The 103 asset managers below reported 45,640,914 for, 4,379,099 against, 25,220 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 45,640,914AGAINST: 4,379,099ABSTAIN: 25,220
Largest asset managers voting on “Election of Directors: Hongbo Lu” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,281,1420 00For
Fidelity2,897,4103,953,343 00Mixed
State Street3,210,7980 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National118,615280,477 00Mixed
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
Lincoln Financial161,2980 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For
Putnam126,4000 00For

Showing the 25 largest of 103 asset managers. All 103 are in the interactive database (link above).

Approval of the Arrowhead Pharmaceuticals, Inc. amended and restated 2021 incentive plan.

No official matchCOMPENSATION

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 108 asset managers

Description as filed by funds: APPROVAL OF THE ARROWHEAD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2021 INCENTIVE PLAN.

The 108 asset managers below reported 50,117,069 for, 57,988 against, 27,721 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 50,117,069AGAINST: 57,988ABSTAIN: 27,721
Largest asset managers voting on “APPROVAL OF THE ARROWHEAD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2021 INCENTIVE PLAN.” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6057 10For
Fidelity6,850,7530 00For
State Street3,210,622176 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For
Putnam126,4000 00For

Showing the 25 largest of 108 asset managers. All 108 are in the interactive database (link above).

Advisory vote to approve executive compensation.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

36% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST
Details: description as filed, votes by 374 asset managers

Description as filed by funds: ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 105 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock263,85314,510,585 00Against
Vanguard5,758,3168,544,297 10Mixed
Fidelity2,840,0014,010,752 00Mixed
State Street3,206,9553,843 00For
Charles Schwab01,191,957 00Against
ALGER INSTITUTIONAL FUNDS0804,346 00Against
ALGER FUNDS0732,137 00Against
Invesco0710,966 00Against
T. Rowe Price0597,841 00Against
Bridge Builder Trust28,891434,727 00Mixed
Jackson National0399,092 00Against
ALGER FUNDS II0374,810 00Against
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya0359,465 00Against
Equitable0309,770 00Against
DRIEHAUS MUTUAL FUNDS0246,088 00Against
Columbia Threadneedle0221,653 00Against
QUANTITATIVE MASTER SERIES LLC0218,394 00Against
Legg Mason0203,339 00Against
Prudential/PGIM0193,603 00Against
Lincoln Financial91,23280,416 00Mixed
First Trust0141,976 00Against
ALGER PORTFOLIOS0132,661 00Against
Putnam0126,400 00Against

Fund voting reports, all 105 managers: 13,399,436 for, 36,662,706 against, 25,221 abstained, 224 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 296 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Avoro Capital Advisors LLC7,371,3010 00For
Fidelity06,718,013 00Against
State Street5,807,29449,413 00For
BlackRock472,6334,499,905 00Mixed
GEODE CAPITAL MANAGEMENT, LLC3,271,0840 00For
FRED ALGER MANAGEMENT, LLC02,564,143 00Against
Janus Henderson02,468,624 00Against
Siren, L.L.C.1,615,4760 00For
DEERFIELD MANAGEMENT COMPANY, L.P.1,591,5590 00For
Charles Schwab01,356,007 00Against
Invesco01,321,542 00Against
PICTET ASSET MANAGEMENT SA01,189,439 00Against
DRIEHAUS CAPITAL MANAGEMENT LLC01,170,616 00Against
Northern Trust1,103,29266,455 00Mixed
Vanguard1,011,100127,769 00Mixed
T. Rowe Price01,000,276 00Against
MELLON INVESTMENTS Corp0857,633 00Against
Fisher Asset Management, LLC0811,995 00Against
UBS0795,961 00Against
PRINCIPAL GLOBAL INVESTORS0716,457 00Against
Vestal Point Capital, LP0697,700 00Against
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP0595,400 00Against
RTW INVESTMENTS, LP585,6820 00For
Voya0496,959 00Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC483,1470 00For

Institutional-manager reports, all 296 managers: 26,124,383 for, 34,266,742 against, 26,360 abstained, 763 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the selection of KPMG LLP as independent auditors of the company for the fiscal year ending September…

No official matchAUDIT-RELATED

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 104 asset managers

Description as filed by funds: RATIFICATION OF THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBER 30, 2026.

The 104 asset managers below reported 50,052,516 for, 1 against, 25,220 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 50,052,516AGAINST: 1ABSTAIN: 25,220
Largest asset managers voting on “RATIFICATION OF THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SE” at Arrowhead Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock14,774,4380 00For
Vanguard14,302,6121 00For
Fidelity6,850,7530 00For
State Street3,210,7980 00For
Charles Schwab1,191,9570 00For
ALGER INSTITUTIONAL FUNDS804,3460 00For
ALGER FUNDS732,1370 00For
Invesco710,9660 00For
T. Rowe Price597,8410 00For
Bridge Builder Trust463,6180 00For
Jackson National399,0920 00For
ALGER FUNDS II374,8100 00For
TIAA371,9850 00For
MUTUAL FUND SERIES TRUST370,0000 00For
Voya359,4650 00For
Equitable309,7700 00For
DRIEHAUS MUTUAL FUNDS246,0880 00For
Columbia Threadneedle221,6530 00For
QUANTITATIVE MASTER SERIES LLC218,3940 00For
Legg Mason203,3390 00For
Prudential/PGIM193,6030 00For
Lincoln Financial171,6480 00For
First Trust141,9760 00For
ALGER PORTFOLIOS132,6610 00For
Putnam126,4000 00For

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

Largest Arrowhead Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 137,391,000 shares outstanding at the time of that meeting.

Fund voting reports: top Arrowhead Pharmaceuticals, Inc. shareholders by shares voted on “Election of Directors: Adeoye Olukotun”, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 10.75%
2Vanguard 10.41%
3Fidelity 4.99%
4State Street 2.34%
5Charles Schwab 0.87%
6ALGER INSTITUTIONAL FUNDS 0.59%
7ALGER FUNDS 0.53%
8Invesco 0.52%
9T. Rowe Price 0.44%
10Bridge Builder Trust 0.34%
Institutional-manager reports: top Arrowhead Pharmaceuticals, Inc. shareholders by shares voted on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.”, 2025-2026
#Asset manager % of shares outstanding
1Avoro Capital Advisors LLC 5.37%
2Fidelity 4.89%
3State Street 4.26%
4BlackRock 3.62%
5GEODE CAPITAL MANAGEMENT, LLC 2.38%
6FRED ALGER MANAGEMENT, LLC 1.87%
7Janus Henderson 1.80%
8Siren, L.L.C. 1.18%
9DEERFIELD MANAGEMENT COMPANY, L.P. 1.16%
10Charles Schwab 0.99%

Reported Arrowhead Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Arrowhead Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock18,161,519 13.22%Form 13F, quarter ended March 31, 2026
Vanguard Group15,293,121 11.13%Form 13F, quarter ended March 31, 2026
Entities affiliated with Avoro Capital Advisors LLC13,985,269 10.18%Proxy statement (DEF 14A), proxy filed January 27, 2026
Avoro Capital Advisors LLC13,823,383 10.06%Schedule 13G, filed August 14, 2026
FMR (Fidelity)7,266,652 5.29%Form 13F, quarter ended March 31, 2026
State Street6,496,130 4.73%Form 13F, quarter ended March 31, 2026
Geode Capital4,278,828 3.11%Form 13F, quarter ended March 31, 2026
Christopher Anzalone3,792,739 2.76%Proxy statement (DEF 14A), proxy filed January 27, 2026
Invesco3,280,647 2.39%Form 13F, quarter ended March 31, 2026
Goldman Sachs1,739,923 1.27%Form 13F, quarter ended March 31, 2026

Percentages above are of 137,391,000 shares outstanding, as reported by Arrowhead Pharmaceuticals, Inc. on its Form 10-Q dated December 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Arrowhead Pharmaceuticals, Inc.'s shareholder meeting held March 19, 2026, in the 2025-2026 proxy season, 377 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 3,827 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Arrowhead Pharmaceuticals, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION. — the reporting funds and managers cast 36% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arrowhead Pharmaceuticals, Inc.’s 10-Q dated December 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Arrowhead Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Arrowhead Pharmaceuticals (ARWR) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/arrowhead-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.